
Pfizer (PFE) investors are bound to be disappointed with the stock’s price action.
With a year-to-date loss of 16.7% as of April 15, the stock is underperforming the S&P 500 Index ($SPX) by a good margin. The global pharmaceutical giant’s underperformance is not limited to 2025. The stock lost 41% in 2023 and 2% in 2024, even as the broader markets delivered double-digit returns in both years.